INS and type 2 diabetes mellitus: In patients, reconstituted HDL (rHDL: apolipoprotein AI + phospholipid complex) treatment reduced plasma glucose in T2DM by increasing plasma insulin and activating AMP‐activated protein kinase in skeletal muscle (Drew et al., 2009).